149 related articles for article (PubMed ID: 14512560)
1. Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.
Neuman de Vegvar HE; Amara RR; Steinman L; Utz PJ; Robinson HL; Robinson WH
J Virol; 2003 Oct; 77(20):11125-38. PubMed ID: 14512560
[TBL] [Abstract][Full Text] [Related]
2. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL
J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347
[TBL] [Abstract][Full Text] [Related]
3. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
[TBL] [Abstract][Full Text] [Related]
6. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
[TBL] [Abstract][Full Text] [Related]
7. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
Munson P; Liu Y; Bratt D; Fuller JT; Hu X; Pavlakis GN; Felber BK; Mullins JI; Fuller DH
Hum Vaccin Immunother; 2018 Jul; 14(7):1820-1831. PubMed ID: 29648490
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
[TBL] [Abstract][Full Text] [Related]
10. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
[TBL] [Abstract][Full Text] [Related]
11. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
12. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
[TBL] [Abstract][Full Text] [Related]
13. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
14. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
[TBL] [Abstract][Full Text] [Related]
15. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
Michelini Z; Negri DR; Baroncelli S; Catone S; Comini A; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Rovetto C; Liljestrom P; Norley S; Heeney J; Titti F
J Med Primatol; 2004 Oct; 33(5-6):251-61. PubMed ID: 15525326
[TBL] [Abstract][Full Text] [Related]
16. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
[TBL] [Abstract][Full Text] [Related]
17. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.
Sadagopal S; Amara RR; Montefiori DC; Wyatt LS; Staprans SI; Kozyr NL; McClure HM; Moss B; Robinson HL
J Virol; 2005 Mar; 79(6):3243-53. PubMed ID: 15731219
[TBL] [Abstract][Full Text] [Related]
18. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques.
Dale CJ; Liu XS; De Rose R; Purcell DF; Anderson J; Xu Y; Leggatt GR; Frazer IH; Kent SJ
Virology; 2002 Sep; 301(1):176-87. PubMed ID: 12359458
[TBL] [Abstract][Full Text] [Related]
19. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles.
Mossman SP; Pierce CC; Watson AJ; Robertson MN; Montefiori DC; Kuller L; Richardson BA; Bradshaw JD; Munn RJ; Hu SL; Greenberg PD; Benveniste RE; Haigwood NL
AIDS Res Hum Retroviruses; 2004 Apr; 20(4):425-34. PubMed ID: 15157361
[TBL] [Abstract][Full Text] [Related]
20. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
